Several researches have indicated that CTX specifically binds to gliomas and tumors of neuroectodermal origin rather than non-neoplastic cells or normal brain [23, 24], and this specific binding to cancer cells is facilitated by matrix metalloproteinase-2 (MMP-2) [25]. This evidence concerns the gene MMP2 and central nervous system cancer.